These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
543 related articles for article (PubMed ID: 28723575)
1. CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors. Bak RO; Porteus MH Cell Rep; 2017 Jul; 20(3):750-756. PubMed ID: 28723575 [TBL] [Abstract][Full Text] [Related]
2. Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors. Hirsch ML; Wolf SJ; Samulski RJ Methods Mol Biol; 2016; 1382():21-39. PubMed ID: 26611576 [TBL] [Abstract][Full Text] [Related]
3. Divergent susceptibilities to AAV-SaCas9-gRNA vector-mediated genome-editing in a single-cell-derived cell population. Morsy SG; Tonne JM; Zhu Y; Lu B; Budzik K; Krempski JW; Ali SA; El-Feky MA; Ikeda Y BMC Res Notes; 2017 Dec; 10(1):720. PubMed ID: 29221488 [TBL] [Abstract][Full Text] [Related]
4. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina. Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510 [TBL] [Abstract][Full Text] [Related]
5. Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration. Bloomer H; Smith RH; Hakami W; Larochelle A Mol Ther; 2021 Apr; 29(4):1611-1624. PubMed ID: 33309880 [TBL] [Abstract][Full Text] [Related]
6. Improved Genome Editing through Inhibition of FANCM and Members of the BTR Dissolvase Complex. de Alencastro G; Puzzo F; Pavel-Dinu M; Zhang F; Pillay S; Majzoub K; Tiffany M; Jang H; Sheikali A; Cromer MK; Meetei R; Carette JE; Porteus MH; Pekrun K; Kay MA Mol Ther; 2021 Mar; 29(3):1016-1027. PubMed ID: 33678249 [TBL] [Abstract][Full Text] [Related]
7. Intracellular generation of single-strand template increases the knock-in efficiency by combining CRISPR/Cas9 with AAV. Xiao Q; Min T; Ma S; Hu L; Chen H; Lu D Mol Genet Genomics; 2018 Aug; 293(4):1051-1060. PubMed ID: 29671068 [TBL] [Abstract][Full Text] [Related]
8. Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina. Yu W; Wu Z Methods Mol Biol; 2019; 1950():123-139. PubMed ID: 30783971 [TBL] [Abstract][Full Text] [Related]
9. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9. Li A; Tanner MR; Lee CM; Hurley AE; De Giorgi M; Jarrett KE; Davis TH; Doerfler AM; Bao G; Beeton C; Lagor WR Mol Ther; 2020 Jun; 28(6):1432-1441. PubMed ID: 32348718 [TBL] [Abstract][Full Text] [Related]
10. Construction and packaging of herpes simplex virus/adeno-associated virus (HSV/AAV) Hybrid amplicon vectors. Saydam O; Glauser DL; Fraefel C Cold Spring Harb Protoc; 2012 Mar; 2012(3):352-6. PubMed ID: 22383640 [TBL] [Abstract][Full Text] [Related]
14. Answered and Unanswered Questions in Early-Stage Viral Vector Transduction Biology and Innate Primary Cell Toxicity for Dudek AM; Porteus MH Front Immunol; 2021; 12():660302. PubMed ID: 34122418 [TBL] [Abstract][Full Text] [Related]
15. Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy. Wang Y; Jiang H; Li M; Xu Z; Xu H; Chen Y; Chen K; Zheng W; Lin W; Liu Z; Lin Z; Zhang M Gene; 2024 Nov; 927():148733. PubMed ID: 38945310 [TBL] [Abstract][Full Text] [Related]